An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
News|Articles|August 11, 2026
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
Fact checked by: Nick Ferreyros, Ron Panarotti
IRA reshapes Medicare drug costs: Part B negotiations loom, pharmacies adapt, and patients gain Part D caps—see impacts on oncology care and access.
Advertisement
Advertisement
The Inflation Reduction Act (IRA) has been law since 2022, but its most consequential provisions for oncology are only beginning to arrive. With the first negotiated drug prices now in effect, Part B drug negotiations on the horizon for 2028, and growing evidence of upstream effects on drug development investment, the IRA is no longer a future policy concern—it is an active one.
Related to this article
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Advertisement
Advertisement